These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19207023)

  • 21. In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity.
    Sanchez-Giron F; Carnevale A
    Pharmacogenomics; 2012 Feb; 13(3):251-2. PubMed ID: 22304575
    [No Abstract]   [Full Text] [Related]  

  • 22. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
    Young B; Squires K; Patel P; Dejesus E; Bellos N; Berger D; Sutherland-Phillips DH; Liao Q; Shaefer M; Wannamaker P
    AIDS; 2008 Aug; 22(13):1673-5. PubMed ID: 18670229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abacavir hypersensitivity.
    Vandekerckhove L; Blot S; Vogelaers D
    N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
    [No Abstract]   [Full Text] [Related]  

  • 24. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 25. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
    Watson ME; Patel LG; Ha B; Wannamaker P; Cuffe R; Shaefer M
    AIDS Patient Care STDS; 2009 Nov; 23(11):957-63. PubMed ID: 19839743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
    Saag M; Balu R; Phillips E; Brachman P; Martorell C; Burman W; Stancil B; Mosteller M; Brothers C; Wannamaker P; Hughes A; Sutherland-Phillips D; Mallal S; Shaefer M;
    Clin Infect Dis; 2008 Apr; 46(7):1111-8. PubMed ID: 18444831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abacavir pharmacogenetics--from initial reports to standard of care.
    Martin MA; Kroetz DL
    Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
    Nolan D
    Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
    Ingelman-Sundberg M
    N Engl J Med; 2008 Feb; 358(6):637-9. PubMed ID: 18256400
    [No Abstract]   [Full Text] [Related]  

  • 35. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
    Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany.
    Wolf E; Blankenburg M; Bogner JR; Becker W; Gorriahn D; Mueller MC; Jaeger H; Welte R; Baudewig M; Walli R; Stoll M
    Eur J Med Res; 2010 Apr; 15(4):145-51. PubMed ID: 20554495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population.
    Badulli C; Sestini R; Sbarsi I; Baroncelli M; Pizzochero C; Martinetti M; Porfirio B
    Pharmacogenomics; 2012 Feb; 13(3):247-9. PubMed ID: 22304574
    [No Abstract]   [Full Text] [Related]  

  • 38. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience.
    Ruiz-Iruela C; Padullés-Zamora N; Podzamczer-Palter D; Alonso-Pastor A; Candás-Estébanez B; Alía-Ramos P; Padró-Miquel A
    Pharmacogenet Genomics; 2016 Aug; 26(8):390-6. PubMed ID: 27195528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of hypersensitivity drug reactions.
    Negrini S; Becquemont L
    Therapie; 2017 Apr; 72(2):231-243. PubMed ID: 28162244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.